Anne Griffiths, MD, of the Hospital for Sick Children in Toronto, spoke to the Advances in Inflammatory Bowel Diseases 2020 virtual meeting on research published this year into the special considerations involved in caring for children with Crohn disease and ulcerative colitis.
Clearly communicating the findings of endoscopy to pathologists, colleagues, and patients requires some standardization in the preparation of endoscopic reports, David T. Rubin, MD, told the attendees of the Advances in Inflammatory Bowel Diseases 2020 virtual meeting on December 11.
Updates to the SECURE-IBD international registry indicate that thiopurines and combination therapies may place patients with inflammatory bowel disease at heightened risk of poor outcomes from COVID-19, while anti-tumor necrosis factor agents may be protective.
Laurent Peyrin-Biroulet, MD, from the University of Nancy, France, spoke to the Advances in Inflammatory Bowel Diseases 2020 virtual meeting about surveillance, prevention, and treatment of cancer among patients with inflammatory bowel disease.
With many agents to choose from and even more slated for the near future, how do you choose the best therapy for your patients with inflammatory bowel disease? William Sandborn, MD, delved into the subject at the Advances in Inflammatory Bowel Diseases 2020 virtual meeting.
Aside from formal measurements of disease activity, there are still some practical approaches to assessing inflammatory bowel disease that can be helpful for clinicians, according to a presentation by Bruce Sands, MD, at the Advances in Inflammatory Bowel Disease 2020 virtual meeting.